The blood-brain barrier (BBB) is a highly selective membrane system that prevents unwanted passage of molecules into the brain extracellular fluid. Consequently, the BBB also significantly hinders the effectiveness of drugs used to treat a number of neurological disorders. Roche has engineered a protein module that can greatly enhance the passage of therapeutic agents across the blood-brain barrier. This 3D medical animation depicts the mechanism by which the “Brain Shuttle” module operates.
GLUTAMATE MODULATION
By
admin
Glutamate is the most abundant excitatory neurotransmitter in the brain. Release of glutamate is essential for normal function of neurons, but the levels of this neurotransmitter must be tightly regulated to avoid toxic effects on neurons. XVIVO partnered with Biohaven to animate the glutamate story.
SB-030 A NOVEL MATRIX REGULATOR
By
admin
XVIVO partnered with Symic Bio to develop an animation that demonstrates the potential efficacy of their molecule, SB-030. SB-030 is delivered to the vessel during a vascular procedure and binds to any exposed matrix inhibiting platelet response to any injury.
PROTAC PLATFORM
By
admin
The biopharmaceutical company Arvinas Inc. has taken a unique approach to develop investigational therapies for hard-to-treat diseases, including cancers. XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and other difficult-to-treat diseases.
LISTERINE SENSITIVITY (PROFESSIONAL)
By
admin
This animation showcases the interplay between the detailed physical structure of channels in the dentin called tubules, the fluid flow inside the tubules, and the signals that propagate from the connected nerves when they are exposed to a trigger such as a drink that is hot, cold, or acidic.
Trumenba MOA
By
Jordan Maire
In this MOA animation, we worked with Pfizer to share their vaccine development against Serogroup B Meningococcal Disease, or MenB. This lethal disease, caused by bacterial meningitis, primarily affects adolescents and young adults.
The blood-brain barrier (BBB) is a highly selective membrane system that prevents unwanted passage of molecules into the brain extracellular fluid. Consequently, the BBB also significantly hinders the effectiveness of drugs used to treat a number of neurological disorders. Roche has engineered a protein module that can greatly enhance the passage of therapeutic agents across the blood-brain barrier. This 3D medical animation depicts the mechanism by which the “Brain Shuttle” module operates.
